Yumanity Therapeutics pulled down a $45 million series A led by Fidelity Management & Research Co. – "the investment group, not the venture group," Tony Coles, chairman and CEO, clarified – in a vote of institutional confidence that "almost never happens" in an early round, he said. The syndicate included seed investor Redmile Group along with Alexandria Venture Investments, Biogen, Sanofi-Genzyme Bioventures and Dolby Family Ventures.